Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma

Conditions:   Clinical Stage I Esophageal Adenocarcinoma AJCC v8;   Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage II Esophageal Adenocarcinoma AJCC v8;   Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage III Esophageal Adenocarcinoma AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Esophageal Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage II Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8
Interventions:   Drug: Carboplatin;   Biological: Ipilimumab;   Biological: Nivolumab;   Drug: Paclitaxel;   Radiation: Radiation Therapy
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting

https://ift.tt/2LxWpd8